Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.

doi:10.1038/s41467-023-44475-6

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.

Nature communications - 2 Jan 2024

Ascierto Paolo A, Casula Milena, Bulgarelli Jenny, Pisano Marina, Piccinini Claudia, Piccin Luisa, Cossu Antonio, Mandalà Mario, Ferrucci Pier Francesco, Guidoboni Massimo, Rutkowski Piotr, Ferraresi Virginia, Arance Ana, Guida Michele, Maiello Evaristo, Gogas Helen, Richtig Erika, Fierro Maria Teresa, Lebbe Celeste, Helgadottir Hildur, Queirolo Paola, Spagnolo Francesco, Tucci Marco, Del Vecchio Michele, Cao Maria Gonzales, Minisini Alessandro Marco, De Placido Sabino, Sanmamed Miguel F, Mallardo Domenico, Paone Miriam, Vitale Maria Grazia, Melero Ignacio, Grimaldi Antonio M, Giannarelli Diana, Dummer Reinhard, Sileni Vanna Chiarion, Palmieri Giuseppe

Abstract excerpt

No prospective data were available prior to 2021 to inform selection between combination BRAF and MEK inhibition versus dual blockade of programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) as first-line treatment options for BRAFV600-mutant melanoma. SECOMBIT (NCT02631447) was a randomized, three-arm, noncomparative phase II trial in which patients were randomized to one of two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Immunotherapy

Share to Ipilimumab

Share to Melanoma

Share to Mitogen-Activated Protein Kinase Kinases

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38167503
DOI: 10.1038/s41467-023-44475-6
PMCID: PMC10761671

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.PMID 38167503Read ↗

Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.Semantic proximity Read ↗

STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.Semantic proximity Read ↗

A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.Semantic proximity Read ↗

Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma.Semantic proximity Read ↗

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.Semantic proximity Read ↗

Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?Semantic proximity Read ↗

Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.Semantic proximity Read ↗

Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.Semantic proximity Read ↗

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.Semantic proximity Read ↗

Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaSemantic proximity Read ↗

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.Semantic proximity Read ↗

Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.